Role of extracorporeal irradiation in malignant bone tumors

Sharma, Dayanand; Rastogi, Sameer; Bakhshi, Sameer; Rath, Goura Kishore; Julka, P.K.; Laviraj, M.A.; Khan, Shah Alam; Kumar, Amandeep

doi:10.4103/0019-509x.123601

Cited by 19 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another previous study by Kamal et al [1,7] reported a five-year survival rate of 54.97 ± 9.8% for LSS using ECI, while Sharma et al [31] affirmatively reported a survival rate as high as 64% for the same surgical technique. Patients with tumor size < 8 cm in diameter with a good type of Huvos always had a better survival rate than those with tumor size > 8 cm in diameter with a poor type of Huvos [1,37].…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Clinical outcome of various limb salvage surgeries in osteosarcoma around knee: Megaprosthesis, extracorporeal irradiation and resection arthrodesis

Kamal

Rubiansyah

2019

Annals of Medicine and Surgery

View full text Add to dashboard Cite

Background We evaluated the outcome and the survival rate of Limb salvage surgeries (LSSs) in osteosarcoma around knee by using megaprosthesis, ECI autograft, and modified arthrodesis of the knee with metallic plus bone cement (MAMC). Methods We reviewed 35 cases of osteosarcoma around the knee that was treated by megaprosthesis, ECI autograft and MAMC from 2012 to 2017. The survival, local recurrence, metastases, complications and functional MSTS score were evaluated for each operation technique. Kaplan-Meier was used to describe the survival rate for each technique. Result Megaprostheses group had an excellent MSTS score (78.7%), the ECI group (72.3%) and MAMC group (68.4%). Local recurrence occurred in the megaprothesis group (0%), the ECI group (9.1%) and MAMC group (20%). Infection occurred in 3 cases of ECI (13.6%) while only 2 (40%) cases in MAMC group and 1 case (12.5%) in the megaprostheses group. Aseptic loosening occurred in the megaprostheses group 1 case (12.5%) and MAMC 1 case (20%). Metastases occurred in 18.2% of the ECI group compared to 25% of the megaprostheses group and 40% of the MAMC group. The megaprosthesis group had an overall survival rate of 90.9 months, whilst the ECI group is on 94.6 months and the MAMC group was 47.2 months. Conclusion Megaprosthesis showed good-excellent functional outcome and survival rate. ECI that is an option in LSS has good functional outcome as well. Knee arthrodesis with MAMC it is still an option to perform LSS even in the advanced local stage of the disease.

show abstract

Section: Discussionmentioning

confidence: 92%

“…Local recurrence also reported as high as 20% [7]. Sharma et al [31] reported an infection rate of 14%. Infection can result into delayed/non‐union of the bone graft, failure of the graft, and delay in the subsequent course of chemotherapy and therefore every effort should be done to minimize the infection [30].…”

Section: Discussionmentioning

confidence: 99%

Clinical outcome of various limb salvage surgeries in osteosarcoma around knee: Megaprosthesis, extracorporeal irradiation and resection arthrodesis

Kamal

Rubiansyah

2019

Annals of Medicine and Surgery

View full text Add to dashboard Cite

show abstract

“…[33] Limb preservation surgery requires special attention to evade future limb length discrepancy in pediatric patients. ECI can effectively prevent the growth of discrepancy frequently observed in prosthetic replacement by evading resection of the normal growth plate and interstitial bone growth from surrounding healthy bones.…”

Section: Managementmentioning

confidence: 99%

“…[34] The main benefit of ECI is the specific structural fit of reimplanted bone part and conservation of joint flexibility. [3334] The reimplantation of the irradiated bone averts some difficulties associated with allograft such as the accessibility of right graft from a bone bank, particularly for pediatric patients, graft rejection, and hazard of viral infection. [34] An autograft is defined as tissue grafted into a new position in the body of the same individual.…”

Section: Managementmentioning

confidence: 99%

Pediatric osteosarcoma: An updated review

Taran¹,

Taran²,

Malipatil³

2017

Indian J Med Paediatr Oncol

155

118

View full text Add to dashboard Cite

Osteosarcoma (OS), the most common type of primary malignant bone tumor, is defined by the presence of malignant mesenchymal cells producing osteoid or immature bone. The peak incidence of the most frequent type of OS, i.e., high-grade central OS, occurs in the second decade of life during the adolescent growth spurt. Most patients suffer from the pain and swelling in the involved region and, usually, seek medical attention. Diagnosis is carried out by conventional radiographs, computed tomography, and magnetic resonance image (MRI). In addition, three-phase bone scans, thallium scintigraphy, dynamic MRI, and positron emission spectroscopy are new innovative promising tools. OS can be treated with surgery, radiotherapy, and chemotherapy. There is a clear need for newer effective agents for patients with OS, especially for patients who afflicted with metastatic and recurrence tumor. Monoclonal antibodies directed against OS may prove useful as treatment, either for drug delivery or for radiopharmaceuticals.

show abstract

“…We also reviewed some recent reports using different techniques to treat primary malignant musculoskeletal tumor, and the MWA therapeutic alternative has more advantages such as ablation in situ, reliable devitalization, less implants requirement, and less osteotomy requirement. The postoperative functional evaluation of MWA showed more superior outcomes than other therapeutic strategies, such as devitalizing autologous tumor-bearing bone in 99% alcohol for 30 min in vitro [10], in 20% sterile saline at 65 °C for 30 min [11], extracorporeal irradiation with X-rays [12], alcohol devitalization combined with prosthesis [13], prosthesis replacements [14], or other biological reconstruction after wide surgical resection [15].…”

Section: Functional Resultsmentioning

confidence: 99%

Clinical evaluations of diaphysis malignant tumors of femur and tibia treated with microwave ablation in situ

Dong

Zhang

et al. 2020

J Orthop Surg Res

View full text Add to dashboard Cite

Background This study was designed to evaluate the clinical outcomes of patients with diaphysis malignant tumors of femur and tibia treated with microwave ablation (MWA) in situ. Methods Retrospective study of 32 patients with diaphysis malignant bone tumors of femur or tibia have been treated by microwave ablation. Instead of en bloc resection, hyperthermia ablation in situ was carried out followed by strengthen procedure. The patients were followed up for a period ranging from 36 to 180 months. Results Twenty-five patients survived over 3 years and all of the patients alive have a satisfactory functional and cosmetic limb. The postoperative survival rate of MWA group was significantly higher than the amputation group in consecutive inclusions. Conclusions MWA is a feasible and effective surgical method for limb salvage operation and it might offer an innovative and distinctive therapeutic alternative for diaphysis malignant bone tumors, which avoiding osteotomy or prosthesis replacement. Level of evidence Level IV, clinical cohort study

show abstract

Role of extracorporeal irradiation in malignant bone tumors

Abstract: Results of our study suggest that ECI is technically feasible in the management of MBT and provides decent local control and short-term survival rates.

Cited by 19 publications

References 16 publications

Clinical outcome of various limb salvage surgeries in osteosarcoma around knee: Megaprosthesis, extracorporeal irradiation and resection arthrodesis

Clinical outcome of various limb salvage surgeries in osteosarcoma around knee: Megaprosthesis, extracorporeal irradiation and resection arthrodesis

Pediatric osteosarcoma: An updated review

Clinical evaluations of diaphysis malignant tumors of femur and tibia treated with microwave ablation in situ

Contact Info

Product

Resources

About